RxDoctor Payments Data

Justin Bennett

Family · Merryville, LANPI 1386637155

Payments from drug & device makers

$626in general payments, 2019–2025

Across 36 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$145
  • Insulet Corporation$75
  • Exact Sciences$53
  • Lilly USA, LLC$49
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$48
  • Teva Pharmaceuticals USA, Inc.$42
  • plus $213 from 10 others

What the payments were for

  • Food & beverage$626100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$626 in reported general payments places this provider in the 50th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$759
Medicare patients
38
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide162$156,265
MounjaroTirzepatide57$72,444
OzempicSemaglutide49$67,675
Budesonide ErBudesonide12$27,361
JardianceEmpagliflozin29$21,751
JanuviaSitagliptin Phosphate25$21,354
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$20,304
EliquisApixaban18$18,208
LinzessLinaclotide19$15,336
EntrestoSacubitril/Valsartan14$12,039
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$11,919
MyrbetriqMirabegron21$9,495
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$8,931
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$4,129
Gabapentin187$3,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$49$228,708219 claims
Novo NordiskOzempic, Levemir$15$70,50061 claims
GSKTrelegy Ellipta$18$20,30433 claims
PfizerEliquis$22$18,20818 claims
AbbVieLinzess$145$15,33619 claims
Astellas Pharma US IncMyrbetriq$33$9,49521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,610 family providers in Louisiana.

Other family in Merryville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →